41 results about "Therapy systemic" patented technology

Methods and systems for the treatment for ALS incorporating stem cells harvested from the subject to be treated. These stem cells may be genetically altered with the addition of several genes of interest. Then, the patient will receive systemic gene therapy for the muscles and directed specifically at motor neurons. In this multi-pronged treatment approach, the stem cells provide immune regulation and the regeneration of motor neurons. And, the new motor neurons carry the added genes, which are protective against motor neuron death from ALS. The systemic therapy increases the amount of genes, which further reduces the effects of ALS. Additional gene therapy administered in the muscle will be further protective of the axon, while maintaining muscle mass and function.

Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.

Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.

In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Copper ion treatments and methods of treatment are provided to treat various body conditions affecting the oral, respiratory and/or otic areas of the body. The copper ion treatments contain copper ions which bring about local and systemic therapeutic effects as a result of contacting anatomical tissue of the oral cavity, the nasal passages or ear canal. The copper ion treatments and methods involve copper ion-containing solutions, copper ion toothpaste and copper ion mouthwash. The copper ion-containing solutions can be delivered to the oral cavity by spraying or swabbing, can be delivered to the nostrils as spray, drops, or by swabbing, and can be delivered to the ear canal as spray, drops, or by swabbing. The copper ion toothpaste is used for brushing the teeth, and the copper ion mouthwash is used for rinsing the mouth.

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive, (b) an active agent comprising a selective COX-2 inhibitory sulfonamide drug of low water solubility, and (c) a solvent system for the active agent, wherein the active agent is in a therapeutically effective total amount and the solvent system is selected with regard to composition and amount thereof to be effective to maintain the active agent substantially completely in solubilized form. A method of local treatment of a site of pain and/or inflammation in a subject comprises applying the composition to a skin surface of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation, and leaving the composition in place for a time period effective to permit delivery of a locally therapeutic amount of the active agent. A method of systemic treatment of a subject having a COX-2 mediated disorder comprises applying the composition to a skin surface of the subject, and leaving the composition in place for a time period effective to permit transdermal delivery of a therapeutic amount of the active agent.

A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein:—the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;—the composition is systemically administered.

The invention relates to an ultrasound mediated mucosal drug delivery system which disperses a large quantity of vesicles containing gases and having acoustic response properties into the traditional liquid type mucosal drug delivery formulation through a formulation technology so as to promote drugs inside the liquid type mucosal drug delivery formulation to faster enter deep tissues and blood circulation to develop therapeutic action by penetrating through a mucosa under ultrasound mediation. The ultrasound mediated mucosal drug delivery system has wide application range and can meet the requirements of mucosa deep tissues or systemic therapy.

Systemic delivery of Modafinil to the nasal mucous membrane elicits rapid systemic therapeutic response with reduced side effects compared to current methods of administration.

The invention discloses application of an ferroptosis inhibitor as an active ingredient in preparation of a drug for treating systemic lupus erythematosus. Researches find that neutrophils of an SLE patient spontaneously generate ferroptosis, and the neutrophils return to normal after effective systemic treatment. The ferroptosis inhibitor liproxstatin-1 (LPX-1) can be used for delaying the deathrate of neutrophils and inhibiting ferroptosis. The Crispr/cas9 technology demonstrates that increased ferroptosis can enable C57/B6 mice to spontaneously develop lupus phenotype. In an MRL/lpr mice model, the LPX-1 treatment can slow down the progress of lupus diseases, and the spleen, lymph node size, nephritis and proteinuria levels, deposition of renal immune complexes, and levels of inflammatory factors in the treated mice are similar to those in the cyclophosphamide-treated group, indicating that the treatment effect of LPX-1 is similar to that of cyclophosphamide. Due to different action mechanisms, the LPX-1 does not have cytotoxicity similar to cyclophosphamide, so that the LPX-1 can be a better lupus treatment drug.